Impact of surveillance-detected metastatic recurrence on treatment outcomes of high-risk melanoma.

Michael Ong(Ottawa Hospital), Andrea Marie Ibrahim(Ottawa Hospital), Horia Marginean(Ottawa Hospital), Carolyn Nessim(University of Ottawa), M LeMay(Ottawa Hospital), Xinni Song
Journal of Clinical Oncology
May 20, 2018
10.1200/jco.2018.36.15_suppl.e21612
Cited by 1

Related Papers

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|392
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
|Annals of Surgical Oncology|2021|251
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2018|216